open access

Vol 22, No 2 (2018)
Position paper
Published online: 2018-06-29
Get Citation

Guidelines of the Pediatric Section of the Polish Society of Hypertension on diagnosis and treatment of arterial hypertension in children and adolescents

Mieczysław Litwin, Anna Niemirska, Łukasz Obrycki, Małgorzata Myśliwiec, Agnieszka Szadkowska, Mieczysław Szalecki, Marta Buraczewska, Grażyna Brzezińska-Rajszys, Sylwester Prokurat, Andrzej Tykarski
DOI: 10.5603/AH.2018.0007
·
Arterial Hypertension 2018;22(2):45-73.

open access

Vol 22, No 2 (2018)
Position paper
Published online: 2018-06-29

Abstract

Presented recommendations are an extended and actualized version of paediatric recommendations of Polish Society of Hypertension published in 2015. Since then, new studies have appeared on this subject, introducing a new classification of hypertension, newly described principles of management in risk groups and methods of assessing hypertensive target organ damage. The presented updated recommendations included changes introduced in the 2016 European Society of Hypertension recommendation and Recommendations of Children’s Memorial Health Institute in Warsaw. Recently published guidelines of American Academy of Paediatrics have been discussed. In the presented issue of guidelines, epidemiological information on the occurrence and incidence of hypertension in developmental age was added and classification of blood pressure values was updated. Subchapters on diagnosis and organ damage assessment, principles of diagnosis and treatment of hypertension in children with diabetes, chronic kidney disease and a subsection discussing diagnostic and therapeutic difficulties with setting blood pressure targets were revised. In addition, the principles of early diagnosis of arterial hypertension in post-hospital care in children born before 33 weeks of gestation published in 2018 as recommendations of the Polish Neonatal Society have been also taken into account.

Abstract

Presented recommendations are an extended and actualized version of paediatric recommendations of Polish Society of Hypertension published in 2015. Since then, new studies have appeared on this subject, introducing a new classification of hypertension, newly described principles of management in risk groups and methods of assessing hypertensive target organ damage. The presented updated recommendations included changes introduced in the 2016 European Society of Hypertension recommendation and Recommendations of Children’s Memorial Health Institute in Warsaw. Recently published guidelines of American Academy of Paediatrics have been discussed. In the presented issue of guidelines, epidemiological information on the occurrence and incidence of hypertension in developmental age was added and classification of blood pressure values was updated. Subchapters on diagnosis and organ damage assessment, principles of diagnosis and treatment of hypertension in children with diabetes, chronic kidney disease and a subsection discussing diagnostic and therapeutic difficulties with setting blood pressure targets were revised. In addition, the principles of early diagnosis of arterial hypertension in post-hospital care in children born before 33 weeks of gestation published in 2018 as recommendations of the Polish Neonatal Society have been also taken into account.
Get Citation

Keywords

arterial hypertension, children, adolescents, newborns, recommendations

About this article
Title

Guidelines of the Pediatric Section of the Polish Society of Hypertension on diagnosis and treatment of arterial hypertension in children and adolescents

Journal

Arterial Hypertension

Issue

Vol 22, No 2 (2018)

Pages

45-73

Published online

2018-06-29

DOI

10.5603/AH.2018.0007

Bibliographic record

Arterial Hypertension 2018;22(2):45-73.

Keywords

arterial hypertension
children
adolescents
newborns
recommendations

Authors

Mieczysław Litwin
Anna Niemirska
Łukasz Obrycki
Małgorzata Myśliwiec
Agnieszka Szadkowska
Mieczysław Szalecki
Marta Buraczewska
Grażyna Brzezińska-Rajszys
Sylwester Prokurat
Andrzej Tykarski

References (139)
  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017; 390(10113): 2627–2642.
  2. Vuguin PM. Animal models for small for gestational age and fetal programming of adult disease. Horm Res. 2007; 68(3): 113–123.
  3. Argente J, Mehls O, Barrios V. Growth and body composition in very young SGA children. Pediatr Nephrol. 2010; 25(4): 679–685.
  4. Tykarski A, Narkiewicz K, Gaciong Z, et al. 2015 Guidelines for the Management of Hypertension Part 1–7. Recommendations of the Polish Society of Hypertension. Arterial Hypertens. 2015; 19(2): 53–83.
  5. Kit BK, Kuklina E, Carroll MD, et al. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report): 555–576.
  6. Baumgartner H, Bonhoeffer P, De Groot NM, et al. Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010; 31(23): 2915–2957.
  7. Urbina E, Alpert B, Flynn J, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension. 2008; 52(3): 433–451.
  8. Standardy opieki ambulatoryjnej nad dzieckiem urodzonym przedwcześnie. Zalecenia Polskiego Towarzystwa Neonatologicznego i Polskiego Towarzystwa Pediatrycznego. Media Press 2017.
  9. Kułaga Z, Litwin M, Grajda A, et al. OLAF Study Group. Oscillometric blood pressure percentiles for Polish normal-weight school-aged children and adolescents. J Hypertens. 2012; 30(10): 1942–1954.
  10. Symonides B, Jędrusik P, Artyszuk L, et al. Different diagnostic criteria significantly affect the rates of hypertension in 18-year-old high school students. Arch Med Sci. 2010; 6(5): 689–694.
  11. Dereziński T, Kułaga Z, Litwin M. Prevalence of arterial hypertension and anthropometrical predictors of elevated blood pressure in 14 years old adolescents. Postępy Nauk Medycznych. 2015; 28(11): 756–759.
  12. Luyckx VA, Perico N, Somaschini M, et al. writing group of the Low Birth Weight and Nephron Number Working Group. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet. 2017; 390(10092): 424–428.
  13. Lurbe E, Cifkova R, Cruickshank JK, et al. Sociedad Europea de Hipertensión, European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009; 27(9): 1719–1742.
  14. Rozporządzenie Ministra Zdrowia z dnia 29 sierpnia 2009 r. w sprawie świadczeń gwarantowanych z zakresu podstawowej opieki zdrowotnej Dz. U. 2009.139.1139.
  15. Constantine E, Merritt C, Constantine E, et al. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care. 2005; 21(6): 391–6; quiz 397.
  16. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009; 24(6): 1101–1112.
  17. Flynn JT, Daniels SR, Hayman LL, et al. American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014; 63(5): 1116–1135.
  18. Kit BK, Kuklina E, Carroll MD, et al. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report): 555–576.
  19. Parati G, Stergiou GS, Asmar R, et al. ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008; 26(8): 1505–1526.
  20. Stergiou GS, Christodoulakis G, Giovas P, et al. Home blood pressure monitoring in children: how many measurements are needed? Am J Hypertens. 2008; 21(6): 633–638.
  21. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103–2116.
  22. Atkins ER, Rodgers A, Xie X, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435–443.
  23. Aatola H, Magnussen CG, Koivistoinen T, et al. Simplified definitions of elevated pediatric blood pressure and high adult arterial stiffness. Pediatrics. 2013; 132(1): e70–e76.
  24. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee On Screening And Management Of High Blood Pressure In Children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3).
  25. Obrycki Ł, Litwin M. Nowe amerykańskie wytyczne postępowania w nadciśnieniu tętniczym u dzieci i młodzieży – najważniejsze zmiany wraz z komentarzem. Stand Med Ped. 2018; 15: 47–55.
  26. Litwin M, Niemirska A, Sladowska-Kozlowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol. 2010; 25(12): 2489–2499.
  27. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20(5): 1251–1260.
  28. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22(2): 107–133.
  29. Litwin M, Niemirska A, Sladowska J, et al. Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol. 2006; 21(6): 811–819.
  30. Khoury PR, Mitsnefes M, Daniels SR, et al. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr. 2009; 22(6): 709–714.
  31. Dallaire F, Slorach C, Hui W, et al. Reference values for pulse wave Doppler and tissue Doppler imaging in pediatric echocardiography. Circ Cardiovasc Imaging. 2015; 8(2): e002167.
  32. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995; 25(5): 1056–1062.
  33. Ong YT, Wong TY, Klein R, et al. Hypertensive retinopathy. N Engl J Med. 2004; 351(22): 2310–2317.
  34. Dodson PM, Lip GY, Eames SM, et al. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. J Hum Hypertens. 1996; 10(2): 93–98.
  35. Feig DI, Johnson RJ. The role of uric acid in pediatric hypertension. J Ren Nutr. 2007; 17(1): 79–83.
  36. Loeffler LF, Navas-Acien A, Brady TM, et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. Hypertension. 2012; 59(4): 811–817.
  37. Reusz GS, Cseprekal O, Temmar M, et al. Reference values of pulse wave velocity in healthy children and teenagers. Hypertension. 2010; 56(2): 217–224.
  38. Van Bortel LM, Laurent S, Boutouyrie P, et al. Artery Society, European Society of Hypertension Working Group on Vascular Structure and Function, European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012; 30(3): 445–448.
  39. Fischer DC, Schreiver C, Heimhalt M, et al. Pediatric reference values of carotid-femoral pulse wave velocity determined with an oscillometric device. J Hypertens. 2012; 30(11): 2159–2167.
  40. Jourdan C, Wühl E, Litwin M, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens. 2005; 23(9): 1707–1715.
  41. Litwin M, Niemirska A. Intima-media thickness measurements in children with cardiovascular risk factors. Pediatr Nephrol. 2009; 24(4): 707–719.
  42. Doyon A, Kracht D, Bayazit AK, et al. 4C Study Consortium. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. Hypertension. 2013; 62(3): 550–556.
  43. Litwin M, Sladowska-Kozlowska K. Diagnostyka różnicowa nadciśnienia tętniczego u młodzieży. In: Litwin M, Prejbisz A, Januszewicz A. ed. Nadciśnienie tętnicze u młodzieży i młodych dorosłych. Medycyna Praktyczna 2011.
  44. Wühl E, Trivelli A, Picca S, et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009; 361(17): 1639–1650.
  45. Litwin M. Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol. 2004; 19(2): 178–186.
  46. Litwin M, Grenda R, Sladowska J, et al. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol. 2006; 21(11): 1716–1722.
  47. Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol. 2008; 23(3): 363–371.
  48. Halbach SM, Martz K, Mattoo T, et al. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr. 2012; 160(4): 621–625.e1.
  49. Kramer AM, van Stralen KJ, Jager KJ, et al. Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. Kidney Int. 2011; 80(10): 1092–1098.
  50. Tkaczyk M, Nowicki M, Bałasz-Chmielewska I, et al. Hypertension in dialysed children: the prevalence and therapeutic approach in Poland--a nationwide survey. Nephrol Dial Transplant. 2006; 21(3): 736–742.
  51. Chavers BM, Solid CA, Daniels FX, et al. Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009; 4(8): 1363–1369.
  52. Chaudhuri A, Sutherland SM, Begin B, et al. Role of twenty-four-hour ambulatory blood pressure monitoring in children on dialysis. Clin J Am Soc Nephrol. 2011; 6(4): 870–876.
  53. Inrig JK, Patel UD, Gillespie BS, et al. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis. 2007; 50(1): 108–18, 118.e1.
  54. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 2007; 11(1): 21–31.
  55. Paglialonga F, Ardissino G, Galli MA, et al. Bioimpedance analysis and cardiovascular status in pediatric patients on chronic hemodialysis. Hemodial Int. 2012; 16 Suppl 1: S20–S25.
  56. Jain SR, Smith L, Brewer ED, et al. Non-invasive intravascular monitoring in the pediatric hemodialysis population. Pediatr Nephrol. 2001; 16(1): 15–18.
  57. Dietel T, Filler G, Grenda R, et al. Bioimpedance and inferior vena cava diameter for assessment of dialysis dry weight. Pediatr Nephrol. 2000; 14(10-11): 903–907.
  58. Laakkonen H, Happonen JM, Marttinen E, et al. Normal growth and intravascular volume status with good metabolic control during peritoneal dialysis in infancy. Pediatr Nephrol. 2010; 25(8): 1529–1538.
  59. Ortega LM, Materson BJ. Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment. J Am Soc Hypertens. 2011; 5(3): 128–136.
  60. Levey AS, Rocco MV, Anderson S, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1): S1–S290..
  61. Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2012; 27(11): 4180–4188.
  62. Hoppe A, von Puttkamer C, Linke U, et al. A hospital-based intermittent nocturnal hemodialysis program for children and adolescents. J Pediatr. 2011; 158(1): 95–9, 99.e1.
  63. Tan BK, Chan C, Davies SJ. Achieving euvolemia in peritoneal dialysis patients: a surprisingly difficult proposition. Semin Dial. 2010; 23(5): 456–461.
  64. Wong H, Mylrea K, Feber J, et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006; 70(3): 585–590.
  65. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014; 129(9): 1048–1078.
  66. Green R, Gu X, Kline-Rogers E, et al. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US Registry. Pediatr Nephrol. 2016; 31(4): 641–650.
  67. Slovut DP, Olin JW, Slovut DP, et al. Fibromuscular dysplasia. N Engl J Med. 2004; 350(18): 1862–1871.
  68. Anderson WP, Kett MM, Stevenson KM, et al. Renovascular hypertension: structural changes in the renal vasculature. Hypertension. 2000; 36(4): 648–652.
  69. Antoniewicz J, Litwin M, Pędich M, et al. Diagnosis and treatment of renovascular hypertension in children and adolescents — single center experience with 87 patients. J Hypertens. 2007; 25(suppl. 2): S332.
  70. Trautmann A, Roebuck DJ, McLaren CA, et al. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol. 2017; 32(3): 495–502.
  71. Tullus K, Roebuck DJ, McLaren CA. Imaging in the evaluation of renovascular disease. Pediatr Nephrol. 2010; 25(6): 1049–1056.
  72. Shroff R, Roebuck DJ, Gordon I, et al. Angioplasty for renovascular hypertension in children: 20-year experience. Pediatrics. 2006; 118(1): 268–275.
  73. Kari JA, Roebuck DJ, McLaren CA, et al. Angioplasty for renovascular hypertension in 78 children. Arch Dis Child. 2015; 100(5): 474–478.
  74. Aggoun Y, Sidi D, Bonnet D. [Arterial dysfunction after treatment of coarctation of the aorta]. Arch Mal Coeur Vaiss. 2001; 94(8): 785–789.
  75. Bhat MA, Neelakandhan KS, Unnikrishnan M, et al. Fate of hypertension after repair of coarctation of the aorta in adults. Br J Surg. 2001; 88(4): 536–538.
  76. Daniels SR. Repair of coarctation of the aorta and hypertension: does age matter. Lancet. 2001; 358(9276): 89–91.
  77. O'Sullivan JJ, Derrick G, Darnell R. Prevalence of hypertension in children after early repair of coarctation of the aorta: a cohort study using casual and 24 hour blood pressure measurement. Heart. 2002; 88(2): 163–166.
  78. de Divitiis M, Pilla C, Kattenhorn M, et al. Ambulatory blood pressure, left ventricular mass, and conduit artery function late after successful repair of coarctation of the aorta. J Am Coll Cardiol. 2003; 41(12): 2259–2265.
  79. Brzezinska-Rajszys G, Qureshi SA, Ksiazyk J, et al. Middle aortic syndrome treated by stent implantation. Heart. 1999; 81(2): 166–170.
  80. Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. Pediatr Nephrol. 2000; 14(5): 422–427.
  81. Araki N, Umemura M, Miyagi Y, et al. Expression, transcription, and possible antagonistic interaction of the human Nedd4L gene variant: implications for essential hypertension. Hypertension. 2008; 51(3): 773–777.
  82. Atanasov AG, Ignatova ID, Nashev LG, et al. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol. 2007; 18(4): 1262–1270.
  83. Bilginturan N, Zileli S, Karacadag S, et al. Hereditary brachydactyly associated with hypertension. J Med Genet. 1973; 10(3): 253–259.
  84. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited--a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994; 330(3): 178–181.
  85. Li A, Tedde R, Krozowski ZS, et al. Molecular basis for hypertension in the. Am J Hum Genet. 1998; 63(2): 370–379.
  86. Toka O, Maass PG, Aydin A, et al. Childhood hypertension in autosomal-dominant hypertension with brachydactyly. Hypertension. 2010; 56(5): 988–994.
  87. Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol. 2009; 24(10): 1929–1937.
  88. Stewart PM. Dexamethasone-suppressible hypertension. Lancet. 2000; 356(9231): 697–699.
  89. Zimmet P, Alberti KG, Kaufman F, et al. IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007; 8(5): 299–306.
  90. Litwin M, Sladowska J, Syczewska M, et al. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007; 20(8): 875–882.
  91. Litwin M, Niemirska A, Sladowska-Kozlowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol. 2010; 25(12): 2489–2499.
  92. Jarosz-Chobot P, Polanska J, Szadkowska A, et al. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia. 2011; 54(3): 508–515.
  93. Fendler W, Borowiec M, Baranowska-Jazwiecka A, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia. 2012; 55(10): 2631–2635.
  94. Margeirsdottir HD, Larsen JR, Brunborg C, et al. Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia. 2008; 51(4): 554–561.
  95. Rodriguez BL, Dabelea D, Liese AD, et al. SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010; 157(2): 245–251.e1.
  96. Knerr I, Dost A, Lepler R, et al. Diabetes Data Acquisition System for Prospective Surveillance (DPV) Scientific Initiative Germany and Austria. Tracking and prediction of arterial blood pressure from childhood to young adulthood in 868 patients with type 1 diabetes: a multicenter longitudinal survey in Germany and Austria. Diabetes Care. 2008; 31(4): 726–727.
  97. Mayer-Davis EJ, Ma Bo, Lawson A, et al. SEARCH for Diabetes in Youth Study Group. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Metab Syndr Relat Disord. 2009; 7(2): 89–95.
  98. Donaghue KC, Wadwa RP, Dimeglio LA, et al. International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes. 2014; 15 Suppl 20: 257–269.
  99. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014; 130(17): 1532–1558.
  100. Afkarian M. Diabetic kidney disease in children and adolescents. Pediatr Nephrol. 2015; 30(1): 65–74; quiz 70.
  101. Pietrzak I, Mianowska B, Gadzicka A, et al. Blood pressure in children and adolescents with type 1 diabetes mellitus--the influence of body mass index and fat mass. Pediatr Endocrinol Diabetes Metab. 2009; 15(4): 240–245.
  102. Delaney A, Pellizzari M, Speiser PW, et al. Pitfalls in the measurement of the nocturnal blood pressure dip in adolescents with type 1 diabetes. Diabetes Care. 2009; 32(1): 165–168.
  103. Suláková T, Janda J, Cerná J, et al. Arterial HTN in children with T1DM--frequent and not easy to diagnose. Pediatr Diabetes. 2009; 10(7): 441–448.
  104. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002; 347(11): 797–805.
  105. Lucini D, Zuccotti G, Malacarne M, et al. Early progression of the autonomic dysfunction observed in pediatric type 1 diabetes mellitus. Hypertension. 2009; 54(5): 987–994.
  106. Basiratnia M, Abadi SF, Amirhakimi GH, et al. Ambulatory blood pressure monitoring in children and adolescents with type-1 diabetes mellitus and its relation to diabetic control and microalbuminuria. Saudi J Kidney Dis Transpl. 2012; 23(2): 311–315.
  107. Basiratnia M, Abadi SF, Amirhakimi GH, et al. Ambulatory blood pressure monitoring in children and adolescents with type-1 diabetes mellitus and its relation to diabetic control and microalbuminuria. Saudi J Kidney Dis Transpl. 2012; 23(2): 311–315.
  108. Tołwińska J, Głowińska-Olszewska B, Bossowski A. Insulin therapy with personal insulin pumps and early angiopathy in children with type 1 diabetes mellitus. Mediators Inflamm. 2013; 2013: 791283.
  109. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014; 130(17): 1532–1558.
  110. Harrington J, Peña AS, Gent R, et al. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. J Pediatr. 2010; 156(2): 237–241.
  111. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004; 25(4): 543–567.
  112. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006; 114(24): 2710–2738.
  113. Afkarian M. Diabetic kidney disease in children and adolescents. Pediatr Nephrol. 2015; 30(1): 65–74; quiz 70.
  114. Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care. 2011; 34(2): 424–429.
  115. Rodriguez BL, Dabelea D, Liese AD, et al. SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010; 157(2): 245–251.e1.
  116. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1735–1741.
  117. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1758–1764.
  118. Springer SC, Silverstein J, Copeland K, et al. American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013; 131(2): e648–e664.
  119. 2015 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin Diabetol. 2015; 4(Suppl. A): A41–A47.
  120. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014; 130(17): 1532–1558.
  121. American Diabetes Association. Standards of medical care in diabetes —2014. Diabetes Care. 2014; 37(Suppl 1): S14–S80.
  122. Chatterjee M, Speiser PW, Pellizzarri M, et al. Poor glycemic control is associated with abnormal changes in 24-hour ambulatory blood pressure in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009; 22(11): 1061–1067.
  123. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60(2): 444–450.
  124. Constantine E, Merritt C, Constantine E, et al. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care. 2005; 21(6): 391–6; quiz 397.
  125. Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children — 1987. Pediatrics. 1987; 79(1): 1–25.
  126. Skalina ME, Kliegman RM, Fanaroff AA. Epidemiology and management of severe symptomatic neonatal hypertension. Am J Perinatol. 1986; 3(3): 235–239.
  127. Friedman AL, Hustead VA. Hypertension in babies following discharge from a neonatal intensive care unit. A 3-year follow-up. Pediatr Nephrol. 1987; 1(1): 30–34.
  128. Buchi KF, Siegler RL. Hypertension in the first month of life. J Hypertens. 1986; 4(5): 525–528.
  129. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. 2012; 27(1): 17–32.
  130. Low JA, Panagiotopoulos C, Smith JT, et al. Validity of newborn oscillometric blood pressure. Clin Invest Med. 1995; 18(3): 163–167.
  131. Langbaum M, Eyal FG. A practical and reliable method of measuring blood pressure in the neonate by pulse oximetry. J Pediatr. 1994; 125(4): 591–595.
  132. Nwankwo MU, Lorenz JM, Gardiner JC. A standard protocol for blood pressure measurement in the newborn. Pediatrics. 1997; 99(6): E10.
  133. Park MK, Menard SM. Normative oscillometric blood pressure values in the first 5 years in an office setting. Am J Dis Child. 1989; 143(7): 860–864.
  134. Park MK, Menard SW, Yuan C. Comparison of auscultatory and oscillometric blood pressures. Arch Pediatr Adolesc Med. 2001; 155(1): 50–53.
  135. O’Brien E, Mee F, Atkins N, et al. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996; 1(1): 55–61.
  136. Peterson AL, Frommelt PC, Mussatto K. Presentation and echocardiographic markers of neonatal hypertensive cardiomyopathy. Pediatrics. 2006; 118(3): e782–e785.
  137. Watkinson M. Hypertension in the newborn baby. Arch Dis Child Fetal Neonatal Ed. 2002; 86(2): F78–F81.
  138. Feld LG, Waz WR. Pharmacologic therapy of hypertension. In: Feld LG. ed. Hypertension in Children. Butterworth-Heinemann, Boston 1997: 133–178.
  139. Luyckx VA, Perico N, Somaschini M, et al. writing group of the Low Birth Weight and Nephron Number Working Group. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet. 2017; 390(10092): 424–428.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl